|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q4 FY2023
As of Jun 30, 2023
|
Q4 FY2022
As of Jun 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development incentives receivable | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | |||||||||||
| Accounts receivable, non-trade | |||||||||||
| Restricted cash | |||||||||||
| Prepaid expenses | |||||||||||
| Total current assets | |||||||||||
| Property and equipment, net | |||||||||||
| Intangible assets, net | |||||||||||
| Operating lease right-of-use assets | |||||||||||
| Restricted cash | |||||||||||
| Goodwill | |||||||||||
| Total assets | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | |||||||||||
| Accrued expenses and other current liabilities | |||||||||||
| Operating lease liability | |||||||||||
| Total current liabilities | |||||||||||
| Operating lease liability, net of current portion | |||||||||||
| Contingent consideration | |||||||||||
| Deferred tax liability | |||||||||||
| Accompanying warrant liability | |||||||||||
| Other non-current liabilities | |||||||||||
| Total liabilities | |||||||||||
| Shareholders’ equity: | |||||||||||
| Common stock, $0.00001 par value, 5,411,334 and 1,978,460 shares issued and outstanding at June 30, 2026 and 2025, respectively | |||||||||||
| Additional paid in capital, net of subscription receivable | |||||||||||
| Accumulated other comprehensive loss, net of tax | |||||||||||
| Accumulated deficit | |||||||||||
| Total shareholders’ equity | |||||||||||
| Total liabilities and shareholders’ equity | |||||||||||
Loading...